Figure 4.

(A–D) BIBN (25 μM) a CGRP antagonist reverses the inhibition of SBCs elicited by CGRP (100 nM), OA-NO₂ (30 μM), CAPS (1 μM), and OAG (50 μM). (E) Pretreatment with indomethacin (INDO, 500 nM) average of 25 min before application of AITC blocks the excitatory effect of AITC (100 μM) on SBCs and unmasks an inhibitory effect that is reversed by BIBN (25 μM; see Figure 5H for graph). (F) BIBN (25 μM) alone elicits a gradual increase in the amplitude of SBCs. (G) Graphs summarizing the magnitude of the inhibition of SBCs (% change of AUC) elicited by CGRP, OAG, OA-NO₂, and CAPS and the block of the inhibition by pretreatment of BIBN. Statistics were performed on raw numbers: 2-tailed t-test, *P < 0.05 and **P < 0.001 and a two-way ANOVA with Bonferroni multiple comparisons post-hoc test (brackets), ^#P < 0.05; n, number of strips.